Properties (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:activeDuring |
gptkb:dalfampridine
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
generic version
|
| gptkbp:brand |
gptkb:dalfampridine
|
| gptkbp:clinicalTrials |
Phase III
improved mobility enhanced quality of life MS treatment guidelines MS walking improvement study improving_walking_in_MS_patients |
| gptkbp:contraindication |
anxiety
fatigue tremors visual disturbances muscle spasms seizure_disorders hypersensitivity_to_dalfampridine |
| gptkbp:dosageForm |
extended-release tablet
|
| gptkbp:drugInterdiction |
available online
diuretics anticonvulsants absorbed in gastrointestinal tract neurological agent other potassium channel blockers |
| gptkbp:formFactor |
oral tablet
|
| gptkbp:hasCapacity |
Acorda Therapeutics support programs
|
| gptkbp:hasPopulation |
adults_with_MS
|
| gptkbp:healthcare |
importance of adherence to therapy
monitor for seizures |
| gptkbp:historical_analysis |
Acorda Therapeutics studies
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ampyra
|
| gptkbp:impact |
as prescribed by physician
|
| gptkbp:interactsWith |
other medications affecting potassium levels
|
| gptkbp:lastProduced |
2010
|
| gptkbp:manufacturer |
gptkb:Acorda_Therapeutics
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:marketingStrategy |
prescription only
|
| gptkbp:numberOfStudents |
5 to 6 hours
|
| gptkbp:offers |
varies by pharmacy
|
| gptkbp:patentExpiration |
2027
|
| gptkbp:researchFocus |
comparative effectiveness research
MS treatment efficacy long-term safety studies patient adherence studies |
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
risk of seizures
|
| gptkbp:sideEffect |
dizziness
headache nausea insomnia urinary tract infection |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
potassium channel blocker
|
| gptkbp:usedFor |
multiple sclerosis
|
| gptkbp:waterManagement |
urine
|